510(k) device
Prosigna Breast Cancer Prognostic Gene Signature Assay
Nanostring Technologies, Inc. · Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer (NYI, Class II) · First FDA decision Sep 6, 2013, newest Nov 7, 2014Breast cancer
Last checked: Nov 21, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
2
Naming "Prosigna"
MAUDE reports
1
Brand "Prosigna", since 2015
PubMed studies
151
Mentioning "Prosigna"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Prosigna Breast Cancer Prognostic Gene Signature Assay
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K141771 · Decided Nov 7, 2014 · 129 days after receipt
Device type: Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer (NYI) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Breast Cancer Assay: Prosigna®Local determinationIn effectL36425CGS Administrators, LLCUpdated Mar 9, 2026
- MolDX: Breast Cancer Assay: Prosigna®Local determinationIn effectL36380Noridian Healthcare Solutions, LLCUpdated Jan 12, 2026
- MolDX: Breast Cancer Assay: Prosigna®Local determinationIn effectL36811WPS Insurance CorporationUpdated Apr 22, 2025
- MolDX: Breast Cancer Assay: Prosigna®Local determinationIn effectL36125Palmetto GBAUpdated Apr 15, 2021
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder CancerLocal determinationIn effectL38586CGS Administrators, LLCUpdated May 11, 2026
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder CancerLocal determinationIn effectL38684WPS Insurance CorporationUpdated Apr 10, 2026
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder CancerLocal determinationIn effectL38647Noridian Healthcare Solutions, LLCUpdated Apr 7, 2026
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder CancerLocal determinationIn effectL38576Palmetto GBAUpdated Apr 7, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Prosigna", any status and sponsor, newest update first.
- The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast CancerActive, not recruiting
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT02653755 · 671 participants · Start Dec 15, 2015 · Primary completion May 15, 2030
Device: Prosigna · For: Breast Cancer Radiation
Sites: Baltimore, Maryland; Boston, Massachusetts; New York, New York · 6 sites in all
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Prosigna", and for the whole product code for context.
This brand
1 reports: 0 malfunction, 1 injury, 0 death
Whole product code NYI
1 reports: 0 malfunction, 1 injury, 0 death
Newest reports for this brand
- PROSIGNAInjury
MW5146345 · Received Sep 29, 2023
Device type: Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer (NYI)
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Prosigna"[tiab]. The summary above synthesizes these.
- Prosigna test in breast cancer: real-life experience.
Hequet D, Harrissart G, Krief D, et al. · Breast Cancer Res Treat · 2021
- Prosigna Assay for Treatment Decisions in Early Breast Cancer: A Decision Impact Study.
Esin E, Yildirim HC, Oksuzoglu B, et al. · J Clin Med · 2024
- Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1).
Ohnstad HO, Blix ES, Akslen LA, et al. · ESMO Open · 2024Multicenter Study, Observational Study
- Prosigna® breast cancer assay: histopathologic correlation, development, and assessment of size, nodal status, Ki-67 (SiNKࡊ) index for breast cancer prognosis.
Baskota SU, Dabbs DJ, Clark BZ, et al. · Mod Pathol · 2021
- Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study.
Kjällquist U, Acs B, Margolin S, et al. · Cancers (Basel) · 2022
- Oncotype DX and Prosigna in breast cancer patients: A comparison study.
Abdelhakam DA, Hanna H, Nassar A · Cancer Treat Res Commun · 2021Comparative Study
- The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
Jensen MB, Lænkholm AV, Nielsen TO, et al. · Breast Cancer Res · 2018Evaluation Study, Research Support, Non-U.S. Gov't
- Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study.
Buus R, Sestak I, Kronenwett R, et al. · J Clin Oncol · 2021Research Support, Non-U.S. Gov't
- Prosigna Risk of Recurrence score and intrinsic subtypes are associated with adjuvant anthracycline chemotherapy benefit in high-risk breast cancer.
Jensen MB, Nielsen TO, Bartlett J, et al. · NPJ Breast Cancer · 2025
- Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study.
Corti C, Chu X, Exman P, et al. · ESMO Open · 2025Observational Study
- Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer.
Lænkholm AV, Jensen MB, Eriksen JO, et al. · Clin Breast Cancer · 2020Research Support, Non-U.S. Gov't
- Breast Cancer: A Heterogeneous Pathology. Prognostic and Predictive Factors - A Narrative Review.
Popa MT, Nodi£i A, Peleaşg TM, et al. · Chirurgia (Bucur) · 2025Review
Other devices of this type
Also filed under product code NYI.
- MammaPrintAgendia, Inc. · De Novo 2020
- Modification to MammaprintAgendia · 510(k) 2009
- MammaPrint FFPE NGS KitAgendia, Inc. · 510(k) 2022
- Mammaprint FfpeAgendia · 510(k) 2015
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.